Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Consensus rating: Five brokerages give Smith & Nephew SNATS an average rating of "Hold" (four hold ratings, one strong-buy) with a 12‑month target price of $34.75.
• Recent stock performance: SNN opened at $31.58, with a 50‑day SMA of $33.77, 200‑day SMA of $33.91 and a one‑year range of $26.33 to $38.79.
• Company results and dividend: The firm reported quarterly EPS of $29.55 on $1.60 billion in revenue and announced a $0.482 per‑share dividend payable May 27 (ex‑dividend March 27).

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) have been assigned an average rating of "Hold" from the five brokerages that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $34.75.

Several analysts have recently weighed in on SNN shares. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Smith & Nephew SNATS in a report on Monday. Wall Street Zen upgraded Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, March 29th. Finally, Canaccord Genuity Group set a $32.00 price target on Smith & Nephew SNATS in a report on Friday.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock opened at $31.58 on Friday. The stock's fifty day simple moving average is $33.77 and its 200 day simple moving average is $33.91. Smith & Nephew SNATS has a one year low of $26.33 and a one year high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The firm had revenue of $1.60 billion for the quarter. On average, equities analysts anticipate that Smith & Nephew SNATS will post 2.29 EPS for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.482 per share. This represents a dividend yield of 304.0%. The ex-dividend date is Friday, March 27th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. River Road Asset Management LLC grew its holdings in Smith & Nephew SNATS by 13.8% during the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider's stock worth $103,996,000 after acquiring an additional 384,926 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Smith & Nephew SNATS by 5.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider's stock worth $67,383,000 after acquiring an additional 100,697 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Smith & Nephew SNATS by 139.9% during the third quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider's stock worth $35,828,000 after purchasing an additional 575,666 shares in the last quarter. Todd Asset Management LLC lifted its position in shares of Smith & Nephew SNATS by 30.2% during the fourth quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider's stock worth $30,992,000 after purchasing an additional 219,348 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Smith & Nephew SNATS by 45.5% during the third quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider's stock valued at $34,038,000 after purchasing an additional 293,418 shares during the last quarter. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.